NGNE Neurogene Inc.
Price Chart
Executive Summary
Neurogene announced completion of dosing in the Embolden registrational trial of NGN-401 for Rett syndrome, exceeding the target with 25 participants dosed due to strong demand. The company also provided an updated corporate presentation highlighting positive interim Phase 1/2 data showing durable, multidomain improvements across all 10 participants, with topline data from Embolden expected in 2H 2027. This is a key clinical milestone de-risking the path to a BLA submission for a potential first-in-class gene therapy in a large rare disease market.
Actionable Insight
The completion of dosing in the registrational trial removes a key execution risk and the strong Phase 1/2 data de-risks the primary endpoint. The next major catalyst is the mid-2026 Phase 1/2 update with 12+ month data for all 10 participants. Traders should monitor for any safety signals or efficacy details at that presentation, as well as the start of the PPQ campaign. The 2H 2027 topline readout is the primary binary event.
Key Facts
- Completed dosing in Embolden registrational trial with 25 participants (exceeded target of 20; pre-specified ITT of up to 24)
- Primary endpoint is a composite of CGI-I score of 3 and gain of any one developmental milestone; 33% (8 of 24) minimum response rate required for success
- Phase 1/2 interim data (cutoff Oct 30, 2025): 100% of 10 participants showed functional improvements across core domains; 35 total developmental milestones gained; 88% achieved improved CGI-I score
- NGN-401 at 1E15 vg dose generally well-tolerated with no HLH cases across Phase 1/2 (n=10) and Embolden (n=25) as of June 7, 2026
- Topline data from Embolden anticipated in 2H 2027; updated Phase 1/2 data with 12+ months follow-up for all 10 participants expected mid-2026
- Cash runway expected to fund operations through Embolden data readout, BLA submission and key pre-launch activities (1Q28)
- Received FDA Breakthrough Therapy, RMAT, START Pilot Program, and other regulatory designations
Financial Impact
No financial figures provided; company is pre-revenue clinical-stage biotech with cash runway to 1Q28
Risk Factors
- Single-arm, open-label trial design introduces potential for placebo effect or rater bias
- Regulatory risk: FDA could change requirements for Embolden trial or BLA submission
- Competition from other Rett syndrome gene therapies in development
- Manufacturing scale-up and PPQ execution risk
- Dependence on positive topline data from Embolden for valuation
Market Snapshot
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001404644-26-000044 |
| Document: ngne-20260608.htm | 0001404644-26-000044 |
| Document: ngne_prxemboldendosingcomp.htm | 0001404644-26-000044 |
| Document: 0001404644-26-000044-index-headers.html | 0001404644-26-000044 |
| Document: 0001404644-26-000044-index.html | 0001404644-26-000044 |
| Document: 0001404644-26-000044.txt | 0001404644-26-000044 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 8, 2026
5d ago
|
8-K
| $26.18 awaiting T+20 | awaiting T+20 | — | $29.10 (+11.15%) |
|
Apr 20, 2026
7w ago
|
8-K
| $27.74 $27.98 | ▲ +0.87% | ▼ −3.34% | $29.10 (+4.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access